# Weill Cornell Medicine (WCM) SPORE in Prostate Cancer

> **NIH NIH P50** · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $2,122,802

## Abstract

OVERALL SUMMARY
Prostate cancer (PCA) is one of the most common cancers in the Western hemisphere, with extreme clinical
and molecular heterogeneity. In 2015, over 221,800 men were diagnosed with—and 27,540 died from—PCA in
the United States. Our Weill Cornell Medicine (WCM) SPORE in PCA will take a novel precision medicine
approach to patient care, which will align our translational research goals with the care of men across the PCA
spectrum. The earliest possible detection of aggressive PCA will avoid less effective late-stage therapies. We
will study how to improve risk assessment in men with localized PCA to enable optimal treatment choices,
including active surveillance (AS). Men with advanced PCA, despite treatment with next generation androgen
deprivation therapy (ADT), succumb to drug resistance and disease progression. We need to optimize care
through novel biomarker and treatment strategies to change lethal PCA to a chronic manageable disease.
We are mindful that knowledge from other fields can augment our research. We will actively use the
Developmental Research Program to bring investigators from across a rich, multi-institutional landscape to
focus on PCA translational research. A sustainable SPORE program requires development of the careers of
junior faculty (Career Enhancement Program), who will be the leaders in the field for years to come. Horizontal
and vertical scientific collaborations will ensure that we leverage expertise and experience across other
SPOREs, the Early Detection Research Network (EDRN), and the Stand Up 2 Cancer (SU2C) and Prostate
Cancer Foundation (PCF) programs. Lastly, we will ensure that resources and data generated from our studies
will be made available to the research community. Our overarching goal is to impact PCA care from initial
diagnosis through management of advanced state disease using precision medicine approaches to improve
current clinical care.
In summary, the WCM SPORE in PCA will be a major hub for paradigm-shifting translational research. We will
establish new approaches to treating PCA, which will result in improved patient survival and quality of life.

## Key facts

- **NIH application ID:** 10227725
- **Project number:** 5P50CA211024-05
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** Massimo Loda
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,122,802
- **Award type:** 5
- **Project period:** 2017-08-30 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10227725

## Citation

> US National Institutes of Health, RePORTER application 10227725, Weill Cornell Medicine (WCM) SPORE in Prostate Cancer (5P50CA211024-05). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10227725. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*